Immunic Historical Cash Flow

IMUX -  USA Stock  

USD 8.47  0.11  1.32%

Analysis of Immunic cash flow over time is an excellent tool to project Immunic future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Cash Flow Business Acquisitions and Disposals of 9.4 M or Issuance Purchase of Equity Shares of 155.8 M as it is a great indicator of Immunic ability to facilitate future growth, repay debt on time or pay out dividends.Financial Statement Analysis is way more than just reviewing and evaluating Immunic prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunic is a good buy for the upcoming year.
Please see Risk vs Return Analysis.

Immunic Historical Statements 

 
Refresh

Immunic Capital Expenditure

(157,526)Share

About Immunic Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Immunic balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Immunic's non-liquid assets can be easily converted into cash.

Immunic Cash Flow Chart

Immunic Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Immunic Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
Immunic Depreciation Amortization and Accretion is fairly stable at the moment as compared to the past year. Immunic reported Depreciation Amortization and Accretion of 39,000 in 2020. Net Cash Flow or Change in Cash and Cash Equivalents is likely to rise to about 105.8 M in 2021, whereas Capital Expenditure is likely to drop (157.5 K) in 2021.

Issuance Purchase of Equity Shares

A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.

Net Cash Flow from Financing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from financing activities; from continuing and discontinued operations. Principal components of financing cash flow are: issuance (purchase) of equity shares; issuance (repayment) of debt securities; and payment of dividends & other cash distributions.

Net Cash Flow from Investing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from investing activities; from continuing and discontinued operations. Principal components of investing cash flow are: capital (expenditure) disposal of equipment Capital Expenditure; business (acquisitions) disposition Net Cash Flow Business Acquisitions and Disposals and investment (acquisition) disposal Net Cash Flow Investment Acquisitions and Disposals.

Net Cash Flow from Operations

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.
Most accounts from Immunic cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Risk vs Return Analysis.Immunic Depreciation Amortization and Accretion is fairly stable at the moment as compared to the past year. Immunic reported Depreciation Amortization and Accretion of 39,000 in 2020. Net Cash Flow or Change in Cash and Cash Equivalents is likely to rise to about 105.8 M in 2021, whereas Capital Expenditure is likely to drop (157.5 K) in 2021.

Immunic cash flow statement Correlations

Immunic Account Relationship Matchups

Immunic cash flow statement Accounts

201620172018201920202021 (projected)
Capital Expenditure(554 K)(678 K)(32 K)(15 K)(146 K)(157.53 K)
Depreciation Amortization and Accretion1.81 M998 K15 K50 K39 K40.03 K
Net Cash Flow or Change in Cash and Cash Equivalents(23.43 M)(3.09 M)8.57 M16.3 M98.08 M105.83 M
Issuance Purchase of Equity Shares32.7 M12.39 M38 M35.16 M144.43 M155.83 M
Net Cash Flow from Financing12.37 M37.98 M19.26 M34.9 M144.43 M155.83 M
Net Cash Flow from Investing(21 K)(678 K)(32 K)10.54 M(146 K)(149.84 K)
Net Cash Flow from Operations(35.77 M)(40.4 M)(9.74 M)(28.55 M)(46.12 M)(49.77 M)
Effect of Exchange Rate Changes on Cash(4 K)1,000(918 K)(589 K)(78 K)(84.16 K)
Share Based Compensation4.03 M4.68 M5.74 M6.51 M2.75 M3.42 M

Immunic Investors Sentiment

The influence of Immunic's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunic. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - IMUX

Immunic Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunic. What is your judgment towards investing in Immunic? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunic using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.